

Inappropriate use of clinical practices in Canada: a systematic review

Janet E. Squires RN PhD, Danielle Cho-Young RN MScN, Laura D. Aloisio RN MScN, Robert Bell MD, Stephen Bornstein PhD, Susan E. Brien PhD, Simon Decary PT PhD, Melissa Demery Varin RN MScN, Mark Dobrow PhD, Carole A. Estabrooks RN PhD, Ian D. Graham PhD, Megan Greenough RN MScN, Doris Grinspun RN PhD, Michael Hillmer PhD, Tanya Horsley PhD, Jiale Hu RN PhD, Alan Katz MBChB MSc, Christina Krause MSc, John Lavis MD PhD, Wendy Levinson MD, Adrian Levy PhD, Michelina Mancuso PT MSc, Steve Morgan PhD, Letitia Nadalin-Penno RN PhD, Andrew Neuner MBA, Tamara Rader MLIS, Wilmer J. Santos RN MScN, Gary Teare DVM PhD, Joshua Tepper MD eMBA, Amanda Vandyk RN PhD, Michael Wilson PhD, Jeremy M. Grimshaw MBChB PhD

■ Cite as: *CMAJ* 2022 February 28;194:E279-96. doi: 10.1503/cmaj.211416

See related article at www.cmaj.ca/lookup/doi/10.1503/cmaj.220134

Abstract

Background: Inappropriate health care leads to negative patient experiences, poor health outcomes and inefficient use of resources. We aimed to conduct a systematic review of inappropriately used clinical practices in Canada.

Methods: We searched multiple bibliometric databases and grey literature to identify inappropriately used clinical practices in Canada between 2007 and 2021. Two team members independently screened citations, extracted data and assessed methodological quality. Findings were synthesized in 2 categories: diagnostics and therapeutics. We reported ranges of proportions of inappropriate

use for all practices. Medians and interquartile ranges (IQRs), based on the percentage of patients not receiving recommended practices (underuse) or receiving practices not recommended (overuse), were calculated. All statistics are at the study summary level.

Results: We included 174 studies, representing 228 clinical practices and 28 900 762 patients. The median proportion of inappropriate care, as assessed in the studies, was 30.0% (IQR 12.0%–56.6%). Underuse (median 43.9%, IQR 23.8%–66.3%) was more frequent than overuse (median 13.6%, IQR 3.2%–30.7%). The most frequently investigated

diagnostics were glycated hemoglobin (underused, range 18.0%–85.7%, $n = 9$) and thyroid-stimulating hormone (overused, range 3.0%–35.1%, $n = 5$). The most frequently investigated therapeutics were statin medications (underused, range 18.5%–71.0%, $n = 6$) and potentially inappropriate medications (overused, range 13.5%–97.3%, $n = 9$).

Interpretation: We have provided a summary of inappropriately used clinical practices in Canadian health care systems. Our findings can be used to support health care professionals and quality agencies to improve patient care and safety in Canada.

As health care systems struggle with sustainability, there is increased recognition that a substantial percentage of the health care received is inappropriate.¹ Inappropriate health care occurs when effective clinical practices are underused, ineffective clinical practices are overused or other practices are misused. It can lead to negative patient experiences,² poor health outcomes^{3,4} and inefficient use of scarce health care resources.⁵ In response, there is widespread professional and policy interest in reducing inappropriate health care in Canada and abroad. For example, in 2014, Choosing Wisely Canada,⁶ a physician-led campaign in partnership with the

Canadian Medical Association, was established. This initiative encourages conversations between clinicians and patients about low-value or overused care in efforts to reduce inappropriate care. Choosing Wisely Canada is endorsed across Canada by all provincial and territorial medical associations (<https://choosingwiselycanada.org/about/>).

Although reducing inappropriate health care is a high priority for health care professionals, agencies and governments in Canada, designing effective initiatives for quality improvement has been a difficult goal to achieve without knowledge of which clinical practices are inappropriately used. This is further challenged because Canada

does not have a mandatory and comprehensive national tracking system for quality. The Canadian Institute for Health Information (CIHI) houses multiple Canadian health databases, but it does not collect information on all clinical practices. Therefore, a systematic synthesis is necessary to provide an overview of inappropriate health care in Canada.⁷ Summaries of inappropriately used clinical practices exist for several countries: United States,^{8,9} United Kingdom¹⁰ and Australia.¹¹ Each of these syntheses found high levels (50% on average) of inappropriately used practices and laid the foundation for several quality improvement initiatives in these countries. We aimed to conduct a systematic review to estimate the nature and amount of inappropriately used clinical practices in Canada.

Methods

Our protocol was published¹² and registered with PROSPERO (the international prospective register of systematic reviews): registration no. CRD42018093495. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)¹³ statement to guide reporting.

Quality of health care is a multidimensional concept. In this review, we defined quality using the framework put forth by the Institute of Medicine,¹⁴ which includes 6 domains of quality care: safe, effective, patient-centred, timely, efficient and equitable. We focused our review on 1 of these quality domains (effectiveness) and reported our findings in terms of inappropriateness (overuse, underuse, misuse) of clinical practices.

Data sources and search strategy

Our search strategy (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.211416/tab-related-content) is reported according to the PRISMA-S guideline.^{15,16} It was executed by an experienced information specialist (T.R.), after peer review by a second information specialist using the Peer Review of Electronic Search Strategies (PRESS) checklist.¹⁷ We searched MEDLINE, EconLit, Science Citation Index Expanded, Arts & Humanities Citation Index, Emerging Sources Citation and Conference Proceedings Citation Index, and Cochrane Library (all databases). Examples of key search terms used for the concept of inappropriate health care are both specific (“unnecessary procedures,” “inappropriate prescribing”) and comprehensive (“comparative effectiveness research,” “delivery of health care,” “quality of health care”). Controlled vocabulary and natural language terms were applied according to the taxonomy of each database for optimal retrieval. We limited our searching to studies published in 2007 onwards; experts in quality improvement across Canada advised us that it takes a minimum of 10 years to notice a trend in data on inappropriate health care, and that studies older than this were unlikely to be useful in determining priorities for future quality improvement activities. We did not apply language limits or study design filters. The grey literature search included targeted, iterative hand searching of 25 government or research organization websites including those of all provincial and territorial ministries of health, provincial health care quality organizations and administrative data facilities, both provincial (e.g., ICES) and national (e.g., CIHI). We conducted 3 consecutive searches, first from Jan. 1, 2007, to May 28, 2018, and

again from June 1, 2018, to Sept. 1, 2019. We conducted a retrospective database search (for additional search terms found in the grey literature) from Jan. 1, 2007, to Sept. 1, 2019. We conducted an updated search using the revised database strategy and of the grey literature from Sept. 1, 2019, to July 20, 2020. We also performed citation checking: we evaluated the reference lists of all included studies to identify additional studies not captured by our search strategy.

Study selection

Two team members independently screened the titles and abstracts identified by the electronic and grey literature searches, and resolved discrepancies by discussion. We included all quantitative study designs reporting data on appropriately or inappropriately used clinical practices in Canada. We defined appropriate and inappropriate practices as ones that did and did not conform fully to an evidence-based recommendation, respectively. Inappropriate care included underuse (failure to provide a clinical practice when patient benefits clearly outweighed the risks), overuse (providing a clinical practice when its potential for harm exceeds the possible benefit) and misuse (when an appropriate clinical practice is selected but a preventable complication occurs and as a result the patient does not receive the full potential benefit of the practice).¹⁸ All practices undertaken by a health care professional in a Canadian health care setting were eligible. In line with previous reviews of inappropriate health care in other countries,^{8–11} we relied on the authors’ identifications of “recommended” clinical practices in the included studies. We included only studies that reported on large or diverse populations, such as the entire nation; 1 or several provinces, territories or cities; or multiple centres.

Data extraction

Data were abstracted in duplicate using a standardized, pilot-tested form in Distiller SR software.¹⁹ In studies where only appropriate health care was reported, we extrapolated inappropriate health care by subtracting the proportion of appropriate care from 100%. We were interested in usual or normal use of clinical practices. Therefore, in longitudinal studies, we extracted the last reported time point, whereas, in experimental studies we extracted baseline measurements for trials with baseline data and postintervention control group data in all other trials.

Assessment of methodological quality

Two reviewers independently assessed the methodological quality of all included studies using the following validated tools: Quality Assessment and Validity Tool for Before/After-Cohort Design Studies,^{20,21} Quality Assessment and Validity Tool for Cross-sectional Studies,^{20–23} Cochrane Risk of Bias Tool 2.0,²⁴ Joanna Briggs Institute Checklist for Quasi-Experimental Studies²⁵ and Joanna Briggs Institute Checklist for Case Series Studies.²⁶ Conflicts regarding all assessments in data extraction and methodological quality were resolved through team discussion.

Data synthesis

We classified all practices first by type of inappropriate use (underuse, overuse or misuse) and, second, as diagnostic or therapeutic. We defined diagnostics as tests used in clinical practice to identify with

high accuracy the condition or disease in a patient, and thus to provide early and proper treatment.²⁷ Therapeutics referred to treatment and care of a patient for the purpose of either preventing or treating disease, or alleviating pain or injury.²⁸ In line with a previous review of studies of health care services in the US,⁹ clinical practices that could function as either diagnostics or therapeutics (e.g., endoscopy and angiography) were classified according to their primary function as stated in the included study. Finally, within diagnostics and therapeutics, we grouped similar practices into subcategories that emerged from the data: diagnostics (referrals, assessments, screening, blood tests, imaging and multiple tests) and therapeutics (acute care procedures, biophysical therapy, psychosocial therapy and medications).

Statistical analysis

To describe the amount of practices identified, we reported proportions and ranges of proportions of inappropriate use for each practice. We determined summaries of inappropriate use by calculating medians and interquartile ranges (IQRs), based on the percentage of patients not receiving a recommended practice (underuse) and receiving a practice when not recommended (overuse). First, we calculated a median proportion and IQR for all inappropriately used practices combined. Second, we calculated an overall median proportion and IQR for all underused practices and all overused practices. Third, for both diagnostics and therapeutics, and their subcategories, we calculated median proportions and

IQRs overall and by kind of inappropriate practice. We assessed for significant differences between kinds of inappropriate practice using the Mann–Whitney *U* Median Test in Statistical Package for the Social Sciences (SPSS) Version 27. We also evaluated for trends over time by reviewing the median proportions for all inappropriate care, diagnostics and therapeutics using the median publication year of 2017 as the cut point (2009–2017 and 2018–2020). All statistics reported are at the study summary level.

We conducted a sensitivity analysis to see if the median proportion estimates changed when methodologically weak studies were omitted.

Ethics approval

This study, being a systematic review, did not require ethics approval.

Results

Figure 1 (PRISMA flow diagram) shows article selection. We screened 16 530 titles and abstracts, of which 930 were potentially relevant, and 174 were included in the systematic review. Studies excluded at full text are detailed in Appendix 2, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.211416/tab-related-content. Of the 174 included studies, 66 (37.9%) evaluated diagnostics, 85 (48.9%) evaluated therapeutics and 23 (13.2%) included both.




Figure 1: Flow chart for selection of articles.

Table 1 (part 1 of 2): Characteristics of the included studies

Characteristic	No. (%) of studies n = 174
Type of inappropriate care*	
Underuse	94 (54.0)
Overuse	95 (54.6)
Misuse	0 (0)
Health care sector*	
Acute or specialty	122 (70.1)
Primary care	57 (32.8)
Rehabilitation	24 (13.8)
Long-term care	23 (13.2)
Home or community	18 (10.3)
Public health	13 (7.5)
Unidentified	13 (7.5)
Province or territory*	
Ontario	98 (56.3)
Alberta	60 (34.5)
British Columbia	27 (15.5)
Quebec	27 (15.5)
Nova Scotia	23 (13.2)
Saskatchewan	17 (9.8)
Manitoba	16 (9.2)
Newfoundland and Labrador	15 (8.6)
New Brunswick	11 (6.3)
Prince Edward Island	9 (5.2)
Yukon	5 (2.9)
Northwest Territories	4 (2.3)
Nunavut	2 (1.1)
Unidentified	13 (7.5)
Sample size	
< 100	9 (5.2)
100–999	59 (33.9)
1000–9999	31 (17.8)
10 000–99 999	24 (13.8)
100 000–1 000 000	15 (8.6)
> 1 000 000	9 (5.2)
Not reported†	27 (15.5)

The 174 included studies included 28 900 762 patients aged from birth to 108 years. All health sectors and Canadian jurisdictions are represented in the sample (summary in Table 1). Appendix 3 (available at www.cmaj.ca/lookup/doi/10.1503/cmaj.211416/tab-related-content) provides greater detail on the included studies.

A detailed assessment of the methodological quality of the included studies is in Appendix 4 (available at www.cmaj.ca/lookup/doi/10.1503/cmaj.211416/tab-related-content). We rated

Table 1 (part 2 of 2): Characteristics of the included studies

Characteristic	No. (%) of studies n = 174
Study design	
Cross sectional	81 (46.5)
Cohort	62 (35.6)
Pre-post	11 (6.3)
Interrupted time series	10 (5.7)
Randomized controlled trial	8 (4.6)
Case series	2 (1.1)
Data source	
Administrative database or population data set	109 (62.6)
Hospital- or setting-specific data	58 (33.3)
Surveys of specific settings or databases	7 (4.0)
Number of specific practices reported	
1	125 (71.8)
≥ 2	49 (28.2)
Evidence source for the recommendation or standard*	
Guideline	165 (94.3)
Systematic review or meta-analysis	29 (16.7)
Quality indicator	1 (0.6)
Sex	
Male and female	103 (59.2)
Female only	15 (8.6)
Male only	4 (2.3)
Not specified or not reported	52 (29.9)
Age, yr	
Adults (≥ 18)	116 (66.7)
Children (1–18)	4 (2.3)
Infants (< 1)	3 (1.7)
Mixed (adults, children or infants)	5 (2.9)
Not specified	46 (26.4)

*Some studies are present in more than 1 category, therefore, values do not add to n = 174 (100.0%).
†Grey literature reports; sample size not reported (mostly studies using large administrative databases).

47 (27.0%) studies as low methodological quality. The most common reasons for lower quality scores were lack of probabilistic sampling in nonpopulation-based studies and lack of reported instrument reliability and validity.

The 174 included studies assessed 228 unique practices. Ninety-four (54.0%) of the studies reported on 144 underused practices (Table 2) and 95 (54.6%) studies reported on 109 overused practices (Table 3); 25 practices were both under- and overused (Table 2 and Table 3). No studies reported misused practices. One hundred twenty (52.6%) of the practices were diagnostic and 108 (47.4%) were therapeutic. Most practices, whether underused or overused, were reported in a single study

Table 2 (part 1 of 4): Underused clinical practices*

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of underuse
Diagnostics				
Laboratory test	Albumin-to-creatinine ratio	Diabetes mellitus, ²⁹⁻³² chronic kidney disease ^{31,33}	5 (7)	26.4–81.6
	Urine collection (24 h)	Kidney stone disease ³⁴	1 (1)	64.5
	Urine protein	Diabetes mellitus ³⁵	1 (1)	26.0
	Sputum sample	COPD ³⁶	1 (1)	97.0
	Oncotype dx prognostic tool	Breast cancer ³⁷	1 (1)	7.0
Referral	Secondary prevention stroke clinic	CVD ³⁸⁻⁴⁰	3 (3)	31.0–45.7
	Dietician or weight loss program	CVD ³¹	1 (1)	81.8
	Smoking cessation program	CVD ³¹	1 (1)	92.3
	Radiation oncologist	Prostate cancer ^{41,42}	2 (2)	20.6–57.0
	Alcohol dependence resource	Alcohol addiction ⁴³	1 (1)	55.0
	Orthopedic pediatric clinic†	Adolescent idiopathic scoliosis ⁴⁴	1 (1)	17.4
	Nephrology specialist	Chronic kidney disease ⁴⁵	1 (1)	55.3
	Pulmonary rehabilitation program	COPD ⁴⁶	1 (1)	34.2
Assessment	Eye examination	Diabetes mellitus ^{29,30,32,35,47-50}	8 (8)	22.9–80.5
	Blood pressure	Diabetes mellitus, ^{29,30,32,47} chronic kidney disease, ³³ CVD, ³¹ cardiac rehabilitation ⁵¹	7 (8)	1.9–92.7
	Electrocardiogram†	Diabetes mellitus, ^{29,30,50} COPD, ³⁶ CVD ³¹	5 (5)	3.6–78.8
	Foot examination	Diabetes mellitus ^{30,32,35,52}	4 (4)	49.0–84.1
	Body mass index	Diabetes mellitus, ^{29,47} cardiac rehabilitation ⁵¹	3 (3)	12.2–65.8
	Neuropathy	Diabetes mellitus ^{29,30,47}	3 (3)	81.9–89.7
	Waist circumference	Diabetes mellitus, ²⁹ CVD, ³¹ elevated cardiometabolic risk ⁵²	3 (3)	53.0–91.3
	Diabetes (6-mo visit)	Diabetes mellitus ³²	1 (1)	36.3
	Swallowing	CVD ^{38,40,53}	3 (3)	35.2–50.5
	Well baby visit (at 18 mo)	Well baby visit ⁵⁴	1 (1)	61.8
	Asthma control	Asthma ⁵⁵	1 (2)	95.0–100.0
	Chronic stable angina	Breast cancer ⁵⁶	1 (1)	32.8
	COPD	Breast cancer ⁵⁶	1 (1)	33.7
	Congestive heart failure	Breast cancer ⁵⁶	1 (1)	26.7
	Transient ischemic attack	Breast cancer ⁵⁶	1 (1)	28.5
	Diabetes	Breast cancer survivors ⁵⁶	1 (1)	19.1
	Anesthesia preassessment	Colorectal surgery ⁵⁷	1 (1)	22.6
	Fracture risk assessment	Fragility fractures ⁵⁸	1 (1)	22.9
	Bowel function	Prostate cancer ⁵⁹	1 (1)	41.5
	Digital rectal examination	Prostate cancer ⁵⁹	1 (1)	6.3
	Dose volume histogram	Prostate cancer ⁵⁹	1 (1)	19.4
	Sexual function	Prostate cancer ⁵⁹	1 (1)	44.5
	Urinary function	Prostate cancer ⁵⁹	1 (1)	8.0
	Audiometric testing	Tympanostomy tube insertion ⁶⁰	1 (1)	27.3
	Impedance testing	Tympanostomy tube insertion ⁶⁰	1 (1)	22.7
	Multiple assessments: expiratory airflow (spirometry, bronchial challenge testing, serial peak flow testing)	Asthma ⁶¹	1 (1)	51.9
	Cervical cancer (multiple components)	Cervical cancer ⁵⁶	1 (1)	29.7
	Colorectal cancer (multiple components)	Colorectal cancer ⁵⁶	1 (1)	51.6
	Skin cancer (annual dermatology examination)	Skin cancer ⁶²	1 (1)	67.3

Table 2 (part 2 of 4): Underused clinical practices*

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of underuse
Screening	Fecal occult blood test	Colorectal cancer (screening) ^{63,64}	2 (2)	49.0–87.9
	Nutrition	Patients admitted to hospital ^{65,66}	2 (3)	29.6–100.0
	Mammography†	Breast cancer (screening) ⁶⁷	1 (1)	73.1
	Depression	Diabetes mellitus ²⁹	1 (1)	92.7
	Syphilis	Prenatal ⁶⁸	1 (1)	79.3
	Retinopathy of prematurity	Premature neonates ⁶⁹	1 (1)	69.6
	Pressure ulcer	Patients with spinal cord injury ⁷⁰	1 (1)	54.3
Blood test	Glycated hemoglobin (HbA _{1c})†	Diabetes mellitus, ^{29–32,35,47,49} chronic kidney disease ³³	9 (9)	18.0–85.7
	Estimated glomerular filtration rate	Diabetes mellitus ^{29–32,47}	5 (5)	12.7–88.7
	Serum creatinine	Diabetes mellitus, ²⁹ chronic kidney disease ³³	2 (3)	14.5–73.3
	Blood culture	COPD, ³⁶ <i>Staphylococcus aureus</i> bacteremia ⁷¹	2 (2)	12.7–95.5
	Fasting blood glucose	CVD, ³¹ cardiac rehabilitation ⁵¹	2 (4)	20.0–57.9
	C-reactive protein	Acute pancreatitis ⁷²	1 (1)	99.6
	Serum lipase	Acute pancreatitis ⁷²	1 (1)	77.4
	Multiple blood tests: lipids (various tests, e.g., total cholesterol, HDL, LDL and triglycerides)†	Diabetes mellitus, ^{29,30,32,47–49} CVD, ³¹ dyslipidemia, ³¹ cardiac rehabilitation ⁵¹	8 (15)	3.2–47.0
	CBC,† electrolytes and cardiac enzymes	COPD ³⁶	1 (1)	54.9
	Gestation diabetes blood test‡	Gestational diabetes mellitus ⁷³	1 (1)	6.4
Imaging	Carotid imaging/Doppler†	CVD ^{31,38,39,53,74–76}	7 (7)	15.6–40.4
	Neuroimaging	CVD ^{38,40}	2 (3)	1.1–10.4
	Carotid imaging/angiography	CVD ⁴⁰	1 (1)	32.5
	Echocardiogram	CVD ³¹	1 (1)	52.1
	Noninvasive cardiac imaging	CVD ⁷⁷	1 (1)	37.5
	Radiography (chest)†	COPD ^{36,50}	2 (2)	3.9–35.0
	CT (head)†	CVA ^{31,53}	2 (2)	12.0–33.8
	CT, ultrasonography	Acute pancreatitis ⁷²	1 (1)	65.3
	CT (abdominal)†	Acute pancreatitis ⁷²	1 (1)	43.9
	Ultrasonography (abdominal)†	Acute pancreatitis ⁷²	1 (1)	29.8
	Breast cancer imaging (mammography, breast ultrasonography or breast MRI)	Breast cancer (in remission) ⁵⁶	1 (1)	35.8
	Dual-energy x-ray absorptiometry†	Osteoporosis ⁵⁶	1 (1)	66.4
	CT or MRI	Prostate cancer ⁵⁹	1 (1)	21.0
	Bone scan†	Prostate cancer ⁵⁹	1 (1)	4.5
Transthoracic echocardiogram†	<i>Staphylococcus aureus</i> bacteremia ⁷¹	1 (1)	14.7	
Multiple diagnostics	Diabetes care (recommended: 4 HbA _{1c} tests, 1 eye test and 1 cholesterol test in a 2-yr period)§	Diabetes mellitus ⁷⁸	1 (1)	60.5
	Ultrasonography with or without fine needle aspiration	Thyroid incidentalomas ⁷⁹	1 (2)	54.0–90.0
	Thyroid-stimulating hormone with thyroid ultrasonography	Thyroid nodules ⁸⁰	1 (1)	47.4
	Prostate cancer assessment (Gleason score, prostate-specific antigen and T-stage)	Prostate cancer ⁵⁹	1 (1)	9.8

(*n* = 174, 68.8%); 42 (16.6%) practices were reported in 3 or more studies and 15 (5.9%) practices were reported in 5 or more studies (Table 2 and Table 3).

Median proportions and IQRs for overall inappropriate use, underuse and overuse by care category (i.e., diagnostics or therapeutics) and their 10 subcategories are summarized in Table 4.

We found that the median proportion of inappropriate use across all practices was 30.0% (IQR 12.0%–56.6%). Proportions of underuse were statistically higher than proportions of overuse for both diagnostic and therapeutic practices. Variance (indicated by the width of the IQR) was also consistently higher for underuse than for overuse.

Table 2 (part 3 of 4): Underused clinical practices*

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of underuse
Therapeutics				
Acute care procedure	Early repeat resection	Bladder cancer, ⁸¹ prostate cancer ⁴¹	2 (2)	51.5–72.2
	Radical prostatectomy	Prostate cancer ⁴¹	1 (1)	83.0
	Fine needle aspiration	Acute pancreatitis ⁷²	1 (1)	97.3
	Endoscopy	Colorectal cancer ⁶³	1 (1)	65.3
	Mechanical bowel preparation	Colorectal surgery ⁸²	1 (1)	41.4
	Carotid endarterectomy or stenting	CVD ⁸³	1 (1)	98.1
Biophysical therapy	Enhanced recovery after surgery (ERAS bundle)	Colorectal surgery, ⁸⁴ breast reconstruction surgery, ⁸⁵ gynecologic surgeries ⁸⁶	3 (4)	28.0–48.8
	Nutrition: clear fluids	Colorectal surgery ⁵⁷	1 (1)	58.3
	Nutrition: liquid calorie supplement	Colorectal surgery ⁵⁷	1 (1)	98.8
	Preoperative: fasting	Colorectal surgery ⁵⁷	1 (1)	91.7
	Postoperative: Foley catheter	Colorectal surgery ⁵⁷	1 (1)	42.9
	Postoperative: mobilization	Colorectal surgery ⁵⁷	1 (1)	90.2
	Influenza vaccine	Diabetes mellitus, ^{30,32} COPD ⁴⁶	3 (3)	20.0–58.5
	Assisted ventilation	COPD ³⁶	1 (1)	97.7
	Pneumococcal vaccine	COPD ⁴⁶	1 (1)	34.0
	Chemotherapy (neoadjuvant or adjuvant)	Bladder cancer ^{87–89}	3 (3)	64.8–81.3
	Radiation therapy†	Prostate cancer, ⁵⁹ bone cancer, ⁹⁰ oral cancer ⁹¹	3 (4)	1.4–92.6
	Nutrition: regular diet	Acute pancreatitis ⁷²	1 (1)	100.0
	Nutrition: enteral nutrition	Acute pancreatitis ⁷²	1 (1)	65.4
	Implantable cardioverter defibrillator†	CVD ⁹²	1 (1)	27.0
	Plasma exchange†	Not specified ⁹³	1 (1)	63.8
	Preoperative: fasting (solids)	Parenteral procedural sedation ⁹⁴	1 (1)	48.1
	Preoperative: fasting (liquids)	Parenteral procedural sedation ⁹⁴	1 (1)	5.0
	Multiple biophysical therapies: radiation therapy with androgen deprivation	Prostate cancer ⁵⁹	1 (1)	68.0
Psychosocial therapy	Counselling: prenatal care (weight gain, smoking, alcohol, working during pregnancy, medications in pregnancy, vitamins and minerals, exercise/active living and nutrition)	Prenatal ^{95–98}	4 (19)	3.2–89.6
	Counselling: smoking cessation	CVD, ^{31,51} diabetes mellitus, ³⁰ elevated cardiometabolic risk ⁵²	4 (4)	9.2–47.2
	Counselling: exercise/active living	CVD, ⁵¹ elevated cardiometabolic risk ⁵²	2 (2)	30.9–85.9
	Counselling: nutrition	Elevated cardiometabolic risk ⁵²	1 (1)	54.2
	Patient education (at least 1 type)	Patients with spinal cord injury ⁷⁰	1 (1)	71.0
	Counselling: preoperative	Colorectal surgery ⁵⁷	1 (1)	58.6
	Education postconcussion	Mild traumatic brain injury or concussion ⁹⁹	1 (1)	52.0
	Counselling: stress management	CVD ⁵¹	1 (1)	18.7
Counselling: self-management of heart disease	CVD ⁵¹	1 (1)	9.2	

Several evidence sources for assessing the appropriateness or inappropriateness of the 228 clinical practices were reported. Most studies ($n = 165$, 94.3%) cited a national or international guideline. Other evidence sources included systematic reviews or meta-analyses ($n = 29$, 16.7%) and quality indicators ($n = 1$, 0.6%). The evidence sources used in each study are listed in Appendix 3.

We found that 120 unique diagnostic practices were investigated in 89 studies; 78 (65.0%) diagnostic practices were underused (Table 2), 56 (46.7%) were overused (Table 3) and 14 (11.7%) were both underused and overused. Diagnostics were inappropriately used, on average, 28% of the time (IQR 12.7%–50.4%). The lowest overall proportion of inappropriate use of

Table 2 (part 4 of 4): Underused clinical practices*

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of underuse
Medication	Statins	CVD, ^{51,100,101} diabetes mellitus, ¹⁰² elevated cardiometabolic risk, ⁵² chronic kidney disease ³³	6 (6)	18.5–71.0
	Multiple medications (cardiovascular)	CVD, ^{31,38,40,103,104} ¶,*,††,‡‡,§§,¶¶ diabetes mellitus, ¹⁰⁴ *** hypertension ¹⁰⁴ †††	5 (9)	3.3–98.8
	ACE inhibitors or ARB	Chronic kidney disease, ³³ CVD, ⁵¹ microalbuminuria, ³⁰ diabetes mellitus ¹⁰²	4 (5)	9.1–77.1
	Antihyperglycemics	Gestational diabetes mellitus, ¹⁰⁵ diabetes mellitus ^{30,31,106}	4 (4)	1.1–70.5
	Antiplatelet therapy	Diabetes mellitus, ¹⁰² CVD ^{51,107}	3 (4)	14.8–93.5
	Proton pump inhibitors†	Diabetes mellitus ¹⁰²	1 (1)	72.3
	Thiazides	Diabetes mellitus ⁵⁰	1 (1)	83.0
	Smoking cessation	CVD, ³¹ COPD ⁴⁶	2 (2)	52.1–76.9
	ASA	CVD ^{31,51}	2 (4)	21.1–30.0
	Tissue plasminogen activator	CVD ^{38,74}	2 (2)	67.6–88.1
	ACE inhibitor, ARB or β-blocker	CVD ³¹	1 (1)	11.5
	β-Blockers	CVD ⁵¹	1 (1)	30.1
	Venous thromboembolism prophylaxis†	Cancer ^{108–111}	4 (7)	7.3–61.3
	Antimicrobials†	Community-acquired pneumonia, ¹¹² urinary tract infections, ¹¹² nonpurulent cellulitis, ¹¹² bacterial infections, ¹¹³ COPD ³⁶	3 (5)	3.8–80.1
	Short-acting β-agonists†	Asthma, ¹¹⁴ COPD ³⁶	2 (2)	41.4–87.6
	Corticosteroids†	COPD ³⁶	1 (1)	72.6
	Corticosteroids	COPD ³⁶	1 (1)	57.0
	Short-acting anticholinergics	COPD ³⁶	1 (1)	51.1
	Domperidone (antiemetic)	Colorectal surgery ⁵⁷	1 (1)	100.0
	Epidural	Colorectal surgery ⁵⁷	1 (1)	76.8
	Magnesium hydroxide	Colorectal surgery ⁵⁷	1 (1)	98.8
	Nonsteroidal anti-inflammatory drugs†	Colorectal surgery ⁵⁷	1 (1)	65.2
	Probiotics	Colorectal surgery ⁵⁷	1 (1)	100.0
	Lipid lowering	Dyslipidemia ³¹	1 (1)	8.5
	Cancer: adjuvant imatinib therapy	Gastrointestinal stromal tumours ¹¹⁵	1 (1)	22.0
	Antihypertensives†	Hypertension ³¹	1 (1)	5.8
	Cancer	Lung cancer ¹¹⁶	1 (1)	93.0
	Oral anticoagulation therapy	Not specified ¹¹⁷	1 (1)	37.0
	Continuous midazolam infusion	Palliative sedation ¹¹⁸	1 (1)	95.8
	Antiemetics	Pediatric oncology ¹¹⁹	1 (1)	71.0
Magnesium sulfate†	Pregnancy: fetal neuroprotection ¹²⁰	1 (1)	23.6	
Cancer: radium-223	Prostate cancer ¹²¹	1 (1)	53.5	
Multiple therapeutics	Endoscopic hemostasis with high-dose IV proton pump inhibitor	Upper gastrointestinal bleeding ¹²²	1 (1)	92.9

Note: ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, ASA = acetylsalicylic acid, CAD = coronary artery disease, CBC = complete blood count, COPD = chronic obstructive pulmonary disease, CT = computed tomography, CVA = cerebral vascular accident (stroke), CVD = cardiovascular disease (includes the 4 main types of CVD: coronary heart disease, stroke/TIA, peripheral arterial/vascular disease and aortic disease), HDL = high-density lipoprotein, IV = intravenous, LDL = low-density lipoprotein, MRI = magnetic resonance imaging, PVD = peripheral vascular disease, TIA = transient ischemic attack.

*A higher number of findings is reported than the number of studies for some categories, because some studies reported more than 1 finding pertinent to that category

†Both underused and overused.

‡Glucose challenge, oral glucose tolerance, HbA_{1c}, or random/fasting glucose.

§60.5% of patients did not receive the recommended biannual diabetic tests. However, 15.3% received no diabetic tests, whereas 60.5% received some but not all tests.

¶Angiotensin-converting enzyme inhibitors/ARBs, β-blockers or mineralocorticoid receptor antagonists.

**β-Blocker, lipid-lowering or other antihypertensive therapy with an ACE inhibitor, ARBs and β-blocker, an ACE inhibitor or ARB.

††Acetylsalicylic acid, clopidogrel, combination of ASA and dipyridole or warfarin.

‡‡Antiplatelet or anticoagulation therapy with a lipid-lowering drug.

§§Angiotensin-converting enzyme inhibitor with a lipid-lowering drug with another antihypertensive drug.

¶¶Antithrombotic drug with an antihypertensive drug with a lipid-lowering drug.

***Angiotensin-converting enzyme inhibitor with an ARB.

†††β-Blocker, with an ACE inhibitor or ARB or both, with an antihypertensive drug.

Table 3 (part 1 of 4): Overused clinical practices

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of overuse	
Diagnostics					
Referral	Neurosurgery	Nonspecific lumbar spine issues ¹²³	1 (1)	43.0	
	Orthopedic pediatric clinic*	Adolescent idiopathic scoliosis ⁴⁴	1 (1)	32.4	
Assessment	Electrocardiogram*	Annual health examination (low-risk adults), ¹²⁴ preoperative testing (low-risk surgeries) ¹²⁵	2 (2)	21.5–31.0	
	Oxygen saturation	Acute bronchiolitis ¹²⁶	1 (1)	42.0	
	Erythema migrans (rash)	Lyme disease ¹²⁷	1 (1)	63.0	
	Pulmonary function test	Noncardiothoracic surgery ¹²⁸	1 (1)	3.0	
	Cardiac stress test	Preoperative testing (low-risk surgeries) ¹²⁵	1 (1)	2.1	
	Multiple assessments: electrocardiogram, cardiac stress test, echocardiogram, chest radiography	Preoperative testing (low-risk surgeries) ¹²⁹	1 (1)	25.1	
	Screening	Papanicolaou test	Cervical cancer (screening) ^{130–133}	4 (4)	8.0–15.7
Mammography*		Breast cancer (screening) ^{129,134}	2 (2)	22.2–25.8	
Colorectal cancer screening (tests not specified)		Colorectal cancer screening (adults 75 yr and older) ¹³³	1 (1)	1.7	
CVD screening		Elevated cardiometabolic risk ⁵²	1 (1)	51.0	
Cell-free DNA prenatal screening		Prenatal ¹³⁵	1 (3)	0.7–17.9	
Blood test	Thyroid-stimulating hormone	Diabetes mellitus, ^{136–138} not specified ^{139,140}	5 (5)	3.0–35.1	
	Glycated hemoglobin (HbA _{1c})*	Diabetes mellitus ^{136,141}	2 (2)	22.9–28.1	
	Lipids (various tests, tests not specified)*	CVD, ¹⁰⁰ not specified ¹³⁶	2 (2)	10.5–18.0	
	Homocysteine	CVD ¹³³	1 (1)	0.4	
	Hypercoagulability testing	Deep vein thrombosis/pulmonary embolism ¹³³	1 (1)	3.5	
	Antinuclear antibody	Not specified ¹⁴²	1 (1)	30.6	
	CBC	Not specified ¹⁴³	1 (1)	5.4	
	Ferritin	Not specified ¹³⁶	1 (1)	35.8	
	Electrolyte panel	Not specified ¹⁴³	1 (1)	35.6	
	Red blood cell folate	Not specified ¹⁴⁴	1 (1)	0.3	
	Vitamin B ₁₂	Not specified ¹³⁶	1 (1)	28.4	
	Vitamin D	Not specified ^{136,140}	2 (2)	0.7–24.5	
	Testosterone	Prostate cancer ¹⁴⁵	1 (1)	3.1	
	Prostate-specific antigen	Suspected prostate cancer ¹³³	1 (1)	55.5	
	Multiple blood tests: CBC,* PT, PTT or metabolic panel	Preoperative (low-risk surgeries) ¹⁴⁶	1 (2)	36.8–63.2	
	Imaging	Radiography (chest)*	Bronchiolitis, ^{147,148} asthma, ¹⁴⁷ preoperative (low risk surgeries), ¹²⁵ annual health examination (adults at low risk) ¹⁴⁹	4 (5)	2.4–34.0
		Transthoracic echocardiogram*	CVD, ^{150–152} preoperative (low-risk surgeries) ¹²⁵	4 (4)	2.9–13.8
Carotid imaging/doppler*		CVD ¹³³	1 (1)	0.1	
Ultrasonography (abdominal)*		Constipation, ¹⁴⁷ abdominal pain, ¹⁴⁷ preoperative (orchiopexy surgery), ¹⁴⁵ not specified ¹⁵³	3 (4)	6.1–58.0	
CT or MRI (lower spine)		Lower back pain ^{129,132,134}	3 (4)	1.6–4.6	
Radiography (type not specified)		Lower back pain ¹³⁴	1 (1)	29.1	
CT (head)*		Febrile convulsion, ¹⁴⁷ seizure, ¹⁴⁷ headache, ¹⁴⁷ delirium ¹²⁹	2 (5)	0.5–24.2	
MRI (type not specified)		Lumbar spine pain, ¹⁵⁴ not specified ¹⁵⁵	2 (2)	1.0–28.5	
Dual-energy x-ray absorptiometry*		Osteoporosis ^{132,133}	2 (2)	11.6–21.0	
Bone scan*		Prostate cancer ^{59,145}	2 (2)	22.0–77.6	
CT or MRI (pelvic)		Prostate cancer ⁵⁹	1 (1)	77.6	
Imaging (type not specified)		Breast cancer (stage I) ¹⁵⁶	1 (1)	79.6	
Radiography (abdominal)		Constipation, ¹⁴⁷ abdominal pain ¹⁴⁷	1 (2)	13.2–25.9	
CT (abdominal)*		Constipation; ¹⁴⁷ abdominal pain ¹⁴⁷	1 (2)	0.1–0.5	
MRI (head)		Concussion, ¹⁴⁷ seizure, ¹⁴⁷ headache ¹⁴⁷	1 (3)	0.4–4.9	
CT pulmonary angiogram	Not specified ¹⁵⁷	1 (1)	27.0		

Table 3 (part 2 of 4): Overused clinical practices

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of overuse
Imaging	CT (type not specified)	Not specified ¹⁵⁵	1 (1)	2.0
	Chest radiography or echocardiogram	Preoperative (cardiovascular surgeries) ¹³⁴	1 (1)	25.1
	Radionuclide imaging	Thyroid nodules ¹⁵⁸	1 (1)	6.3
	Ultrasonography (carotid)	Not specified ¹⁵³	1 (1)	25.2
	Ultrasonography (pelvic)	Not specified ¹⁵³	1 (1)	1.6
	Ultrasonography (soft tissue)	Not specified ¹⁵³	1 (1)	2.4
	Ultrasonography (thyroid)	Not specified ¹⁵³	1 (1)	18.8
	Multiple imaging (cardiac imaging: coronary CT, cardiac stress test)	CVD ¹³³	1 (1)	1.0
	Cardiac imaging (transthoracic echocardiography transesophageal echocardiography, single-photon emission tomography myocardial perfusion imaging, diagnostic cardiac catheterization)	Suspected CVD ¹⁵²	1 (1)	5.0
	Combined surveillance breast imaging (mammogram, breast ultrasonography and breast MRI)	Breast cancer survivors ⁵⁶	1 (1)	4.0
Head scans (brain/cranial radiography, CT, MRI)	Minor head trauma ¹²⁹	1 (1)	28.9	
CT or MRI (head and lumbar)	Not specified ¹⁵⁹	1 (1)	12.0	
Therapeutics				
Acute care procedure	Cesarean delivery	Pregnant women ^{160,161}	2 (5)	21.7–69.0
	Angiography	CVD, ¹⁶² ischemic heart disease ¹⁶³	2 (2)	10.8–16.0
	Cystoscopy	Asymptomatic microscopic hematuria ¹⁶⁴	1 (1)	57.1
	Peripherally inserted central catheters	Not specified ¹⁶⁵	1 (1)	16.5
Biophysical therapy	Implantable cardioverter defibrillator therapy*	After out-of-hospital cardiac arrest, ¹⁶⁶ had life-threatening ventricular tachyarrhythmia or at high risk for sudden cardiac death, ¹⁶⁷ cardiovascular arrhythmia ¹⁶⁸	3 (3)	< 1.0–16.7
	Cardiac resynchronization therapy	Had life-threatening ventricular tachyarrhythmia or at high risk for sudden cardiac death ¹⁶⁷	1 (1)	10.0
	Withdrawal of life-sustaining treatment	Cardiovascular arrest ¹⁶⁹	1 (1)	32.0
	Red blood cell transfusions	Not specified ^{170,171}	2 (2)	22.0–61.0
	Intravenous immune globulin transfusion	Not specified ¹⁷²	1 (1)	56.7
	Plasma exchange*	Not specified ¹⁷³	1 (1)	28.6
	Bowel preparation	Colorectal surgery ⁵⁷	1 (1)	32.4
	Nasogastric tube	Colorectal surgery ⁵⁷	1 (1)	7.4
	Albumin transfusion	Fluid resuscitation ¹⁰⁹	1 (1)	20.0
	Radiation therapy*	Oral cavity squamous cell carcinoma ⁹¹	1 (1)	1.0
Physical restraints	Physical restraint use in long-term care facilities ¹⁷⁴	1 (1)	7.8	
Medication (single class or single medication)	Antimicrobials*	Various bacterial infections (pneumonia, urinary tract infection, pharyngitis, cellulitis), ¹¹³ ventilator-associated pneumonia, ¹⁷⁵ <i>Clostridium difficile</i> infection, ¹⁷⁶ acute pancreatitis-infected necrosis, ⁷² asymptomatic bacteriuria, ^{177,178} nonbacterial acute upper respiratory infection, ¹⁷⁹ acute pancreatitis (general), ⁷² <i>Staphylococcus aureus</i> bacteremia, ⁷¹ viral infection ¹¹³	8 (11)	11.8–76.0
	Antipsychotics	Studies of potentially inappropriate medications, ^{174,180–183} Parkinson disease ¹⁸⁴	6 (6)	5.6–76.5
	Opioids	Dental pain, ^{185,186} studies of potentially inappropriate medications ^{187–189}	5 (7)	0.1–23.9

Table 3 (part 3 of 4): Overused clinical practices

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of overuse
Medication (single class or single medication)	Benzodiazepines	Sedative hypnotics for insomnia, agitation or delirium; ¹²⁹ studies of potentially inappropriate medications ^{182,183,187}	4 (4)	11.1–50.7
	Nonsteroidal anti-inflammatory drugs*	Studies of potentially inappropriate medications ^{182,183,187,190}	4 (4)	0.5–21.7
	Antihyperglycemics*	Diabetes mellitus and chronic kidney disease, ¹⁹¹ studies of potentially inappropriate medications ^{183,190}	3 (3)	3.3–21.0
	Proton pump inhibitors*	Studies of potentially inappropriate medications ^{182,183,187}	3 (3)	8.3–27.0
	Short-acting β-agonists*	Asthma ^{114,192}	2 (2)	3.2–5.3
	Antileukotriene	Asthma ⁶¹	1 (1)	5.9
	Asthma	Asthma ⁶¹	1 (1)	79.3
	Corticosteroids*	Asthma ⁶¹	1 (1)	33.5
	Antidepressants	Studies of potentially inappropriate medications ^{182,183}	2 (2)	5.0–10.0
	Antispasmodics	Studies of potentially inappropriate medications ^{182,183}	2 (2)	0.1–1.0
	Antithrombotic	Studies of potentially inappropriate medications ^{182,183}	2 (2)	0.1–0.1
	Barbiturates	Studies of potentially inappropriate medications ^{182,183}	2 (2)	0.1–0.1
	Central α ₁ -blockers	Studies of potentially inappropriate medications ^{182,183}	2 (2)	1.3–4.3
	First-generation antihistamines	Studies of potentially inappropriate medications ^{182,183}	2 (2)	1.9–4.4
	Peripheral α ₁ blockers	Studies of potentially inappropriate medications ^{182,183}	2 (2)	1.2–4.7
	Skeletal muscle relaxants	Studies of potentially inappropriate medications ^{182,183}	2 (2)	3.0–5.2
	Antidiuretic (desmopressin)	Studies of potentially inappropriate medications ¹⁸³	1 (1)	0.1
	Non-benzodiazepine and benzodiazepine receptor agonist hypnotics	Studies of potentially inappropriate medications ^{182,183}	2 (2)	0.01–0.01
	Sedative hypnotics	Studies of potentially inappropriate medications ¹⁹⁰	1 (1)	9.0
	Selective α ₁ -adrenergic blocking agents (e.g., alfuzosin, tamsulosin, silodosin)	Studies of potentially inappropriate medications ¹⁸⁷	1 (1)	5.6
	Magnesium sulfate*	Fetal neuroprotection ¹²⁰	1 (1)	9.3
	Quetiapine	Insomnia (children) ¹²⁹	1 (1)	0.2
	Venous thromboembolism prophylaxis*	Not specified ¹⁰⁹	1 (1)	45.3
	Multiple: potentially inappropriate: multiple medications	End-stage kidney disease, ¹⁹³ studies of potentially inappropriate medications ^{182,194–200}	9 (9)	13.5–97.3
	Antiparkinsonian: multiple medications	Studies of potentially inappropriate medications ^{182,183}	2 (2)	0.1–0.3
	Analgesics (pentazocine and meperidine)	Studies of potentially inappropriate medications ¹⁸³	1 (1)	0.1
	Cardiovascular: multiple medications	Studies of potentially inappropriate medications ¹⁸²	1 (1)	1.6
	Cardiovascular (disopyramide, dronedarone, digoxin, short-acting nifedipine, amiodarone)	Studies of potentially inappropriate medications ¹⁸³	1 (1)	0.6
	Gastrointestinal (other than proton pump inhibitors): multiple medications	Studies of potentially inappropriate medications ¹⁸²	1 (1)	0.1
	Genitourinary: multiple medications	Studies of potentially inappropriate medications ¹⁸²	1 (1)	0.2
	Pain medications: other than NSAIDs and skeletal muscle relaxants: multiple medications	Studies of potentially inappropriate medications ¹⁸²	1 (1)	0.3
	Polypharmacy in older adults: multiple medications	Studies of potentially inappropriate medications ²⁰¹	1 (1)	48.0
	Potentially inappropriate: nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, antiplatelets or anticoagulants, oral corticosteroids, alendronate, ACE inhibitors, angiotensin II receptor blockers, diuretics or β-blockers	Studies of potentially inappropriate medications ²⁰²	1 (1)	72.0

Table 3 (part 4 of 4): Overused clinical practices

Care subcategory	Clinical practice	Disease or condition	No. of studies (No. of findings)	Percentage or range of overuse
	Potentially inappropriate: benzodiazepines, H2-receptor antagonists, antipsychotics, anticholinergic	Studies of potentially inappropriate medications ²⁰³	1 (1)	44.3
	Pharmacotherapy (epinephrine, salbutamol, hypertonic saline, corticosteroid)	Acute bronchiolitis ¹⁴⁸	1 (1)	46.0

Note: ACE = angiotensin-converting enzyme, CAD = coronary artery disease, CBC = complete blood count, CT = computed tomography, CVD = cardiovascular disease (includes the 4 main types of CVD: coronary heart disease, stroke/TIA, peripheral arterial/vascular disease, aortic disease), H2 = histamine type 2, MRI = magnetic resonance imaging, NSAID = nonsteroidal anti-inflammatories, PT = prothrombin time, PTT = partial thromboplastin time.

*Both underused and overused.

Table 4: Inappropriately used clinical practices

Category of care		Inappropriate use (total)			Underuse			Overuse		
		No. of total practices (no. of unique practices)*	No. of studies (no. of findings)	Median (IQR), %	No. of total practices	No. of studies (no. of findings)	Median (IQR), %	No. of total practices	No. of studies (no. of findings)	Median (IQR), %
Diagnostics	Laboratory test	5 (5)	9 (11)	48.4 (26.4–73.0)	5	9 (11)	48.4 (26.4–73.0)	0	0 (0)	–
	Referral	10 (9)	11 (13)	43.0 (31.7–56.2)	8	10 (11)	45.7 (31.0–57.0)	2	2 (2)	–
	Assessment	35 (34)	32 (66)	38.2 (24.0–63.7)	29	25 (59)	39.1 (24.3–65.8)	6	6 (7)	25.1 (3.0–42.0)
	Screening	12 (11)	17 (21)	29.6 (14.1–68.3)	7	9 (10)	68.3 (53.0–82.7)	5	8 (11)	14.2 (2.9–22.2)
	Blood test	25 (22)	27 (65)	24.7 (16.4–38.8)	10	14 (42)	27.8 (18.2–49.0)	15	13 (23)	22.4 (3.5–35.1)
	Imaging	43 (35)	34 (77)	13.8 (4.5–29.0)	15	15 (25)	21.3 (13.4–36.7)	28	21 (52)	9.7 (3.0–24.9)
	Multiple diagnostics	4 (4)	4 (5)	54.0 (28.6–75.3)	4	4 (5)	54.0 (28.6–75.3)	0	0 (0)	–
	Subtotal	134 (120)	89 (258)	28.0 (12.7–50.4)	78	52 (163)	35.2 (21.3–61.8)	56	42 (95)	13.2 (3.3–28.1)
Therapeutics	Acute care procedure	10 (10)	12 (16)	53.5 (21.8–71.4)	6	6 (7)	72.2 (51.5–97.3)	4	6 (9)	22.0 (16.3–56.3)
	Biophysical therapy	29 (26)	28 (42)	45.8 (19.2–64.8)	18	18 (28)	57.5 (36.2–78.0)	11	12 (14)	18.4 (6.4–32.1)
	Psychosocial therapy	9 (9)	11 (31)	37.8 (30.5–54.2)	9	11 (31)	37.8 (30.5–54.2)	0	0 (0)	–
	Medications	70 (62)	69 (159)	25.9 (5.8–60.2)	32	34 (71)	51.1 (24.0–71.0)	38	39 (88)	10.6 (1.7–38.5)
	Multiple therapeutics	1 (1)	1 (1)	–	1	1 (1)	–	0	0 (0)	–
	Subtotal	119 (108)	108 (249)	34.0 (10.0–61.1)	66	60 (138)	51.1 (30.1–71.0)	53	55 (111)	13.6 (3.0–38.9)
Total		253 (228)	174 (507)	30.0 (12.0–56.6)	144	94 (301)	43.9 (23.8–66.3)	109	95 (206)	13.6 (3.2–30.7)

Note: IQR = interquartile range.

*Unique practices: excludes practices that are both underused and overused ($n = 25$).

Table 5: Trends in amount of inappropriately used practices over time

Category of care	2009–2017 <i>n</i> = 92		2018–2020 <i>n</i> = 80	
	No. of studies (no. of findings)	Median (IQR), %	No. of studies (no. of findings)	Median (IQR), %
Diagnostics subtotal	52 (154)	28.5 (17.0–50.4)	35 (99)	26.7 (7.0–42.2)
Therapeutics subtotal	58 (128)	42.2 (18.9–67.3)	50 (120)	24.5 (3.9–55.0)
Total	92 (282)	32.6 (18.0–58.7)	80 (219)	25.9 (5.0–52.1)

Note: IQR = interquartile range. Multiple diagnostics subcategory removed: only 1 data point in 2018–2020; multiple therapeutics subcategory removed: only 1 data point in 2009–2017.

diagnostics was in imaging tests (median 13.8%, IQR 4.5%–29.0%), whereas the highest proportions were in laboratory tests (median 48.4%, IQR 26.4%–73.0%). The most frequently investigated underused diagnostics were glycated hemoglobin (blood tests), lipid tests (blood tests) and diabetic eye examinations (assessments). Glycated hemoglobin, assessed in 9 studies, had underuse proportions of 18.0%–85.7%. Lipid tests, assessed in 8 studies, had underuse proportions of 3.2%–47.0%. Diabetic eye examinations, also assessed in 8 studies, had underuse proportions of 22.9%–80.5%. The most frequently investigated overused diagnostic was thyroid-stimulating hormone (blood tests), investigated in 5 studies with overuse proportions ranging from 3.0%–35.1%. The next most frequently investigated overused diagnostics, evaluated in 4 studies each, were radiography of the chest (imaging; overused 2.4%–34.0%), Papanicolaou test (screening; overused 8.0%–15.7%) and transthoracic echocardiogram (imaging; overused 2.9%–13.8%).

We found that 108 therapeutic practices were investigated in 108 studies: 66 (61.1%) therapeutics were underused (Table 2), 53 (49.1%) were overused (Table 3) and 11 (10.2%) were both underused and overused. Therapeutics were inappropriately used, on average, 34.0% of the time (IQR 10.0%–61.1%), with the lowest overall proportions of inappropriate use for medications (median 25.9%, IQR 5.8%–60.2%) and the highest proportions for acute care procedures (median 53.5%, IQR 21.8%–71.4%). Although acute care procedures (e.g., carotid endarterectomy) had the highest median proportion of inappropriate use, they were among the least investigated therapeutics (10 procedures in 12 studies). The most frequently investigated therapeutics that were underused were statins (medications), with underuse proportions of 18.5%–71.0% (*n* = 6), and combinations of cardiovascular drugs (medications), with underuse proportions of 3.3%–98.8% (*n* = 5). The most frequently investigated overused therapeutics were also all within the medication subcategory: overuse ranged from 11.8% to 76.0% for antimicrobials (*n* = 8), 5.6%–76.5% for antipsychotics (*n* = 6) and 0.1%–23.9% for opioids (*n* = 5).

Table 5 displays the medians for inappropriate use over the 12 years of data included in this review, for which we used the median publication year of 2017 as the comparison point (Table 5). The largest difference was in therapeutics, which showed a decrease of 17.7% in inappropriate care in recent years. When assessed by subcategory, only medications showed a noteworthy reduction in inappropriate care (41.0% down to 14.0%). This reduc-

tion was due to fewer medications being overused (38% down to 5.0%); underuse of medications increased during the same time frame (46.0% up to 63.0%) (Appendix 5, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.211416/tab-related-content).

When we omitted studies that were methodologically weak, median proportion estimates were largely unchanged (Appendix 6, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.211416/tab-related-content).

Interpretation

We identified 174 studies that investigated 228 unique clinical practices that were underused or overused in Canada over the last decade. The dominant finding from our review is that there are large gaps between the care people should receive and the care they do receive. We found that, on average, 30.0% of the care received by people in Canada as assessed in the included research papers using the Institute of Medicine's definitions of underuse and overuse,¹⁸ was deemed inappropriate. This was true for both diagnostic and therapeutic practices across different health sectors, all age groups, and whether the nation or select cities, provinces or territories were evaluated.

Estimates of the amount of inappropriate care from our review are similar to those reported in reviews from other countries. In the germinal 1998 review of inappropriate health care in the US,⁸ patients received inappropriate care in 45% of encounters. Like our findings, there was substantial heterogeneity in inappropriate use in the US review based on the clinical practices evaluated, ranging from 21.3% to 89.5%. Similar findings were reported in reviews from other countries: in the UK,¹⁰ 51%–97% of care was reported to be inappropriate, and in Australia,¹¹ 10.0%–87.0% was inappropriate.

Inappropriate care is a pressing problem in health care, largely because it causes iatrogenic harm to patients and often interferes with the delivery of high-value care.²⁰⁴ It also leads to negative patient experiences,² poor health outcomes^{3,4} and inefficient use of scarce health care resources.⁵ Previous reviews^{9–11} on inappropriate care provided much needed stimuli to the field of health care quality by elevating global recognition that inappropriate care is not only a serious and widespread problem, but one to which no health sector is immune. These reviews also laid the foundation for several successful quality improvement initiatives in their countries (e.g., the *100 000 Lives* and *Protecting 5 Million Lives from Harm* campaigns in

the US).^{18,19} The findings from our review provide examples of clinical practices that are underused and overused in Canada. Knowledge of these indicators is necessary to underpin initiatives in Canada to improve the quality of health care. Our results can be used by provincial and territorial governments and quality improvement organizations to prioritize future quality improvement initiatives. Our findings also provide a critically needed benchmark tool against which future progress in quality improvement can be measured.

Proportions of inappropriate use of many of the clinical practices identified in our review varied widely; however, some practices were studied frequently and others infrequently. As a result, large gaps in our knowledge of inappropriately used clinical practices in Canada remains. Although we were able to provide a substantial listing and summary of inappropriately used practices in Canada, it is not a comprehensive summary of all practices delivered in the Canadian health care system. Additional research, especially on practices not yet investigated and on those less frequently investigated, are critical next steps to expand the list of inappropriately used practices.

Limitations

Studies were heterogeneous with respect to the practices investigated, populations used, data collection time points and how inappropriate care was measured. Although we retrieved and evaluated each cited practice recommendation, it was not feasible to assess the quality of the evidence behind each recommendation. There may be valid reasons not reported in the included studies for why some patients did or did not receive a recommended practice. Our review was limited to studies that evaluated practices against a criterion standard such as a guideline recommendation; this may have led to some missed reports on inappropriate care. We only captured instances of appropriate or inappropriate care that were studied and, thus, where researchers speculated that there was a problem of appropriateness. Many of the included practices were evaluated in a single study, which limited the conclusions that could be drawn on these practices. Finally, a common reason for lower quality scores (i.e., lack of probabilistic sampling in non-population-based studies) may have affected the reliability of some of the inappropriate proportions that we reported.

Conclusion

We found that many clinical practices received by people in Canada are inappropriate; whether that practice is diagnostic or therapeutic, it frequently does not meet recommended standards. Although we identified a considerable range of clinical practices that are inappropriate, it is not an exhaustive listing of all practices delivered in Canada. Further research is necessary to expand on this list. Clinicians and organizations could use the list of clinical practices from this review (especially the 42 most-studied practices) to identify priorities for their work on quality improvement.

References

- Appropriateness in health care. Ottawa: Canadian Medical Association; 2015. Available: <https://policybase.cma.ca/documents/policypdf/PD15-05.pdf> (accessed 2021 Dec. 6).
- Bourne RB, Chesworth BM, Davis AM, et al. Patient satisfaction after total knee arthroplasty: Who is satisfied and who is not? *Clin Orthop Relat Res* 2010;468:57-63.
- Pimlott NJG, Hux JE, Wilson LM, et al. Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. *CMAJ* 2003;168:835-9.
- Hall RD, Khan F, O'Callaghan C, et al. Ontario Stroke Evaluation Report 2014. On target for stroke prevention and care. Toronto: ICES; 2014. Available: <https://www.deslibris.ca/ID/245240> (accessed 2021 July 29).
- McAlister FA. The treatment of hypertension in Canada: Are we making progress? *CMAJ* 1999;161:713-4.
- Choosing Wisely Canada [home page]. Available: <https://choosingwiselycanada.org/> (accessed 2021 July 29).
- Lavis JN, Wilson MG, Grimshaw JM. Evidence brief: optimizing clinical practice in Ontario based on data, evidence and guidelines. Hamilton (ON): McMaster Health Forum; 2015. Available: <https://macsphere.mcmaster.ca/handle/11375/17248> (accessed 2021 Dec. 6).
- Schuster MA, McGlynn EA, Brook RH. How good is the quality of health care in the United States? *Milbank Q* 1998;76:517-63.
- Korenstein D, Falk R, Howell EA, et al. Overuse of health care services in the United States: an understudied problem. *Arch Intern Med* 2012;172:171-8.
- Seddon ME, Marshall MN, Campbell SM, et al. Systematic review of studies of quality of clinical care in general practice in the UK, Australia and New Zealand. *Qual Health Care* 2001;10:152-8.
- Runciman WB, Hunt TD, Hannaford NA, et al. CareTrack: assessing the appropriateness of health care delivery in Australia. *Med J Aust* 2012;197:100-5.
- Squires JE, Graham ID, Grinspun D, et al. Inappropriateness of health care in Canada: a systematic review protocol. *Syst Rev* 2019;8:50.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.
- Institute of Medicine (US) Committee on Quality of Health Care in America. *Crossing the quality chasm: a new health system for the 21st century*. Washington (DC): National Academies Press (US); 2001. Available: <http://www.ncbi.nlm.nih.gov/books/NBK222274/> (accessed 2021 Nov. 24).
- Bramer WM, de Jonge GB, Rethlefsen ML, et al. A systematic approach to searching: an efficient and complete method to develop literature searches. *J Med Libr Assoc* 2018;106:531-41.
- Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. *Syst Rev* 2021;10:39.
- Sampson M, McGowan J, Cogo E, et al. An evidence-based practice guideline for the peer review of electronic search strategies. *J Clin Epidemiol* 2009;62:944-52.
- Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. *JAMA* 1998;280:1000-5.
- MacAdden V. Citing DistillerSR in publications and presentation. Ottawa: DistillerSR; 2021. Available: <https://blog.evidencepartners.com/citing-distiller-in-publications-and-presentations> (accessed 2021 May 17).
- Estabrooks CA, Cummings GG, Olivo SA, et al. Effects of shift length on quality of patient care and health provider outcomes: systematic review. *Qual Saf Health Care* 2009;18:181-8.
- Cummings G, Lee H, Macgregor T, et al. Factors contributing to nursing leadership: a systematic review. *J Health Serv Res Policy* 2008;13:240-8.
- Estabrooks CA, Floyd JA, Scott-Findlay S, et al. Individual determinants of research utilization: a systematic review. *J Adv Nurs* 2003;43:506-20.
- Squires JE, Estabrooks CA, Gustavsson P, et al. Individual determinants of research utilization by nurses: a systematic review update. *Implement Sci* 2011;6:1.
- RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. *Cochrane Methods Equity*; 2021. Available: <https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials> (accessed 2021 May 17).
- The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews: checklist for quasi-experimental studies (non-randomized experimental studies). Adelaide (Australia): The Joanna Briggs Institute; 2017:1-7.
- The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews: checklist for case series. Adelaide (Australia): The Joanna Briggs Institute; 2017:1-7.
- Bolboacă SD. Medical diagnostic tests: a review of test anatomy, phases, and statistical treatment of data. *Comput Math Methods Med* 2019;2019:1891569.
- Rakel RE. Therapeutics. Chicago: Encyclopedia Britannica. Available: <https://www.britannica.com/science/therapeutics> (accessed 2021 May 27).
- Harris S, Paquette-Warren J, Roberts S, et al. Results of a mixed-methods evaluation of partnerships for health: a quality improvement initiative for diabetes care. *J Am Board Fam Med* 2013;26:711-9.
- Khadilkar A, Whitehead J, Taljaard M, et al. Quality of diabetes care in the Canadian Forces. *Can J Diabetes* 2014;38:11-6.

31. Liddy C, Singh J, Hogg W, et al. Quality of cardiovascular disease care in Ontario, Canada: missed opportunities for prevention — a cross sectional study. *BMC Cardiovasc Disord* 2012;12:74.
32. Vitale M, Xu C, Lou W, et al. Impact of diabetes education teams in primary care on processes of care indicators. *Prim Care Diabetes* 2020;14:111-8.
33. Bello AK, Ronskley PE, Tangri N, et al. Quality of chronic kidney disease management in Canadian primary care. *JAMA Netw Open* 2019;2:e1910704.
34. Harmouch SS, Abou-Haidar H, ElHawary H, et al. Metabolic evaluation guidelines in patients with nephrolithiasis: Are they being followed? Results of a national, multi-institutional, quality-assessment study. *Can Urol Assoc J* 2018;12:313-8.
35. *Diabetes care gaps and disparities in Canada*. Ottawa: Canadian Institute for Health Information; 2009:1-21. Available: https://secure.cihi.ca/free_products/Diabetes_care_gaps_disparities_aib_e.pdf (accessed 2021 Apr. 29).
36. McKenna P, MacLeod K, Le C, et al. Management of acute exacerbation of COPD in rural Alberta emergency departments. *Can J Rural Med* 2015;20:7-14.
37. Martel S, Lambertini M, Simon R, et al. Adherence to guidelines in requesting Oncotype dx in a publicly funded health care system. *Curr Oncol* 2018;25:e311-8.
38. Hall R, Khan F, O'Callaghan C, et al. Ontario Stroke Evaluation Report 2012: prescribing system solutions to improve stroke outcomes. Toronto: ICES; 2012. Available: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2012/Ontario-Stroke-Evaluation-Report-2012> (accessed 2021 Apr. 29).
39. Hall R, Khan F, Levi J, et al. Ontario and LHIN 2015/16 Stroke Report Cards and Progress Reports: setting the bar higher. Toronto: ICES; 2017. Available: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2017/Stroke-Report-Cards> (accessed 2021 Dec. 24).
40. Kapral MK, Fang J, Silver FL, et al. Effect of a provincial system of stroke care delivery on stroke care and outcomes. *CMAJ* 2013;185:E483-91.
41. Alghamdi M, Taggar A, Tilley D, et al. An audit of referral and treatment patterns of high-risk prostate cancer patients in Alberta. *Can Urol Assoc J* 2016;10:410-5.
42. Taggar A, Alghamdi M, Tilly D, et al. Assessing guideline impact on referral patterns of post-prostatectomy patients to radiation oncologists. *Can Urol Assoc J* 2016;10:314-8.
43. Minian N, Baliunas D, Noormohamed A, et al. The effect of a clinical decision support system on prompting an intervention for risky alcohol use in a primary care smoking cessation program: a cluster randomized trial. *Implement Sci* 2019;14:85.
44. Beauséjour M, Goulet L, Ehrmann Feldman D, et al. Scoliosis Referral Project members. Pathways of healthcare utilisation in patients with suspected adolescent idiopathic scoliosis: a cross-sectional study. *BMC Health Serv Res* 2015;15:500.
45. Brimble KS, Boll P, Grill AK, et al. Impact of the KidneyWise toolkit on chronic kidney disease referral practices in Ontario primary care: a prospective evaluation. *BMJ Open* 2020;10:e032838.
46. Wirth IM, Penz ED, Marciniuk DD. Examination of COPD management in patients hospitalized with an acute exacerbation of COPD. *Can J Respir Crit Care Sleep Med* 2020 Feb. 21 [Epub ahead of print]. doi: 10.1080/24745332.2020.1719941.
47. Hayward MN, Pace R, Zaran H, et al.; FORGE AHEAD Program Team. Closing the Indigenous health gap in Canada: results from the TransFORMation of IndiGENous PrimARy HEALthcare delivery (FORGE AHEAD) program. *Diabetes Res Clin Pract* 2020;162:108066.
48. Barker LC, Kurdyak P, Jacob B, et al. Quality of diabetes care for individuals with comorbid chronic psychotic illness: a sex-based analysis. *J Womens Health (Larchmt)* 2018;27:290-6.
49. Kurdyak P, Vigod S, Duchon R, et al. Diabetes quality of care and outcomes: comparison of individuals with and without schizophrenia. *Gen Hosp Psychiatry* 2017;46:7-13.
50. *Quality Monitor: 2011 report on Ontario's health system*. Toronto: Health Quality Ontario:1-164. Available: <https://www.hqontario.ca/portals/0/Documents/pr/qmonitor-full-report-2011-en.pdf> (accessed 2021 Apr. 29).
51. Somanader DS, Chessex C, Ginsburg L, et al. Quality and variability of cardiovascular rehabilitation delivery: applying the Canadian quality indicators. *J Cardiopulm Rehabil Prev* 2017;37:412-20.
52. Teoh H, Després J-P, Dufour R, et al. Identification and management of patients at elevated cardiometabolic risk in Canadian primary care: How well are we doing? *Can J Cardiol* 2013;29:960-8.
53. Hall RE, Sondergaard D, Wodchis WP, et al. Trajectories of stroke care in Ontario: Which path to best care? *Can J Neurol Sci* 2017;44:261-6.
54. Guttmann A, Klein-Geltink J, Kopp A, et al. Uptake of the new fee code for Ontario's enhanced 18-month well baby visit: a preliminary evaluation. Toronto: ICES; 2011. Available: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2011/Uptake-of-the-new-fee-code> (accessed 2021 Apr. 29).
55. Price C, Agarwal G, Chan D, et al. Large care gaps in primary care management of asthma: a longitudinal practice audit. *BMJ Open* 2019;9:e022506.
56. McBride ML, Groome PA, Decker K, et al. Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study. *BMC Cancer* 2019;19:659.
57. Aarts M-A, Okrainec A, Glicksman A, et al. Adoption of enhanced recovery after surgery (ERAS) strategies for colorectal surgery at academic teaching hospitals and impact on total length of hospital stay. *Surg Endosc* 2012;26:442-50.
58. Allin S, Munce S, Schott A-M, et al. Quality of fracture risk assessment in post-fracture care in Ontario, Canada. *Osteoporos Int* 2013;24:899-905.
59. Brundage M, Danielson B, Pearcey R, et al. A criterion-based audit of the technical quality of external beam radiotherapy for prostate cancer. *Radiother Oncol* 2013;107:339-45.
60. Beyea JA, Rosen E, Stephens T, et al. Audiometric testing guideline adherence in children undergoing tympanostomy tubes: a population-based study. *Otolaryngol Head Neck Surg* 2018;158:1127-33.
61. Aaron SD, Vandemheen KL, FitzGerald JM, et al.; Canadian Respiratory Research Network. Reevaluation of diagnosis in adults with physician-diagnosed asthma. *JAMA* 2017;317:269-79.
62. Chan A-W, Fung K, Austin PC, et al. Improved keratinocyte carcinoma outcomes with annual dermatology assessment after solid organ transplantation: population-based cohort study. *Am J Transplant* 2019;19:522-31.
63. Solbak NM, Xu J-Y, Vena JE, et al. Patterns and predictors of adherence to colorectal cancer screening recommendations in Alberta's Tomorrow Project participants stratified by risk. *BMC Public Health* 2018;18:177.
64. *Colorectal cancer screening in Canada: monitoring and evaluation of quality indicators — results report 2013 to 2014*. Toronto: Canadian Partnership Against Cancer; 2017. Available: <https://www.partnershipagaincancer.ca/topics/colorectal-cancer-screening-quality-indicators-2017/> (accessed 2021 Apr. 29).
65. Keller HH, Valaitis R, Laur CV, et al. Multi-site implementation of nutrition screening and diagnosis in medical care units: success of the More-2-Eat project. *Clin Nutr* 2019;38:897-905.
66. Andrade L, Moran K, Snelling SJ, et al. Beyond BMI: a feasibility study implementing NutriSTEP in primary care practices using electronic medical records (EMRs). *Health Promot Chronic Dis Prev Can* 2020;40:1-10.
67. Pelletier E, Daigle J-M, Defay F, et al. Frequency and determinants of a short-interval follow-up recommendation after an abnormal screening mammogram. *Can Assoc Radiol J* 2016;67:322-9.
68. Plitt SS, Osman M, Sahni V, et al. Examination of a prenatal syphilis screening program, Alberta, Canada: 2010–2011. *Can J Public Health* 2016;107:e285-90.
69. Gupta V, Whelan KF, Schneider L, et al. National variations in retinopathy of prematurity screening criteria in Canada: existent guidelines and actual practice patterns. *Can J Ophthalmol* 2012;47:473-8.
70. Scovil CY, Delparte JJ, Walia S, et al.; SCI KMN Group. Implementation of pressure injury prevention best practices across 6 Canadian rehabilitation sites: results from the Spinal Cord Injury Knowledge Mobilization Network. *Arch Phys Med Rehabil* 2019;100:327-35.
71. Martin L, Harris MT, Brooks A, et al. Management and outcomes in patients with *Staphylococcus aureus* bacteremia after implementation of mandatory infectious diseases consult: a before/after study. *BMC Infect Dis* 2015;15:568.
72. Greenberg JA, Hsu J, Bawazeer M, et al. Compliance with evidence-based guidelines in acute pancreatitis: an audit of practices in University of Toronto hospitals. *J Gastrointest Surg* 2016;20:392-400.
73. Donovan LE, Savu A, Edwards AL, et al. Prevalence and timing of screening and diagnostic testing for gestational diabetes mellitus: a population-based study in Alberta, Canada. *Diabetes Care* 2016;39:55-60.
74. Hall R, Linkewich B, Khan F, et al. Ontario and LHIN 2013/14 Stroke Report Cards and Progress Reports: driving knowledge exchange and implementing stroke best practices. Toronto: ICES; 2015. Available: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2015/Ontario-Stroke-Report-Cards> (accessed 2021 Apr. 29).
75. Hall R, Khan F, Levi J, et al. Ontario and LHIN 2014/15 Stroke Report Cards and Progress Reports: active knowledge exchange to drive system integration and stroke best practices. Toronto: ICES; 2016. Available: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2016/Ontario-Stroke-Report-2016> (accessed 2021 Dec. 29).
76. Pardhan A, Sharp S, Yearwood K, et al. Ontario and LHIN 2017/18 Stroke Report Cards and Progress Reports. Toronto: CorHealth Ontario; 2019. Available: <https://www.corhealthontario.ca/Ontario-&-LHIN-2017-18-Stroke-Report-Cards-&-Progress-Reports.pdf> (accessed 2021 Dec. 12).
77. Baine KR, Durham D, Zheng Y, et al. Utilization and costs of noninvasive cardiac tests after acute coronary syndromes: insights from the Alberta COAPT Study. *CJC Open* 2019;1:76-83.

78. Hsu JH, Calzavara A, Vigod S, et al. Factors associated with diabetes care quality among patients with schizophrenia in Ontario, Canada. *Psychiatr Serv* 2020;71:188-91.
79. Wong J, Liu K, Siu C, et al. Management of PET diagnosed thyroid incidentalomas in British Columbia Canada: critical importance of the PET report. *Am J Surg* 2017; 213:950-7.
80. Wanis K, Oucharek J, Groot G. Quality of thyroid referrals in Saskatchewan. *Qual Prim Care* 2013;21:247-52.
81. Gotto GT, Shea-Budgell MA, Ruether JD. Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta. *Can Urol Assoc J* 2016;10:33-8.
82. Eskicioglu C, Pearsall E, Victor JC, et al. A multifaceted knowledge translation strategy can increase compliance with guideline recommendations for mechanical bowel preparation. *J Gastrointest Surg* 2015;19:39-45.
83. Hall R, O'Callaghan C, Bayley M, et al. Ontario Stroke Evaluation Report 2010: technical report. Toronto: ICES; 2010. Available: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2010/Ontario-Stroke-Evaluation-Technical-Report> (accessed 2021 Apr. 29).
84. Martin P, Tamblin R, Benedetti A, et al. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. *JAMA* 2018;320:1889-98.
85. Redwood JN, Matkin AE, Temple-Oberle CF. Adoption of enhanced recovery after surgery protocols in breast reconstruction in Alberta is high before a formal program implementation. *Plast Reconstr Surg Glob Open* 2019;7:e2249.
86. Bisch SP, Wells T, Gramlich L, et al. Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: system-wide implementation and audit leads to improved value and patient outcomes. *Gynecol Oncol* 2018;151:117-23.
87. Booth CM, Karim S, Brennan K, et al. Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing? *Urol Oncol* 2018;36:89.e13-e20.
88. Siemens DR, Visram K, Wei X, et al. Effect of centralization on complex surgical care: a population-based case study of radical cystectomy. *Can Urol Assoc J* 2020;14:91-6.
89. Gotto GT, Shea-Budgell M, Rose MS, et al. Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. *Can Urol Assoc J* 2015;9:236-41.
90. Olson RA, Tiwana MS, Barnes M, et al. Use of single- versus multiple-fraction palliative radiation therapy for bone metastases: population-based analysis of 16,898 courses in a Canadian province. *Int J Radiat Oncol Biol Phys* 2014;89:1092-9.
91. Hinthar A, Nakoneshny SC, Dort JC, et al. Historical compliance rates for providing postoperative radiotherapy in oral cavity squamous cell carcinoma. *Head Neck* 2016;38:1525-9.
92. Steinberg C, Cheung CC, Wan D, et al. Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) study. *Can J Cardiol* 2020;36:1269-77.
93. Sawler D, Parker A, Britto J, et al. Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: a 10-year provincial retrospective cohort study. *Thromb Res* 2020;193:53-9.
94. Bhatt M, Johnson DW, Taljaard M, et al.; Sedation Safety Study Group of Pediatric Emergency Research Canada. Association of preprocedural fasting with outcomes of emergency department sedation in children. *JAMA Pediatr* 2018;172:678-85.
95. McDonald SD, Pullenayegum E, Bracken K, et al. Comparison of midwifery, family medicine, and obstetric patients' understanding of weight gain during pregnancy: a minority of women report correct counselling. *J Obstet Gynaecol Can* 2012;34:129-35.
96. Vinturache A, Winn A, Mannion C, et al. Women's recall of health care provider counselling on gestational weight gain (GWG): a prospective, population-based study. *BMC Pregnancy Childbirth* 2019;19:136.
97. Vinturache AE, Winn A, Tough SC. Recall of prenatal counselling among obese and overweight women from a Canadian population: a population based study. *Matern Child Health J* 2017;21:2092-101.
98. McDonald SD, Pullenayegum E, Taylor VH, et al. Despite 2009 guidelines, few women report being counseled correctly about weight gain during pregnancy. *Am J Obstet Gynecol* 2011;205:333.e1-6.
99. Rowe BH, Eliyahu L, Lowes J, et al. A prospective evaluation of the influence of an electronic clinical practice guidelines on concussion patients' future activities and outcomes. *J Emerg Med* 2018;54:774-84.
100. Brown F, Singer A, Katz A, et al. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. *Can Fam Physician* 2017;63:e495-503.
101. Chen G, Farris MS, Cowling T, et al. Treatment and low-density lipoprotein cholesterol management in patients diagnosed with clinical atherosclerotic cardiovascular disease in Alberta. *Can J Cardiol* 2019;35:884-91.
102. Greiver M, Kalia S, Moineddin R, et al. Impact of the diabetes Canada guideline dissemination strategy on dispensed vascular protective medications for older patients in Ontario, Canada: a linked EMR and administrative data study. *BMC Health Serv Res* 2020;20:370.
103. Diamant MJ, Virani SA, MacKenzie WJ, et al. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure. *ESC Heart Fail* 2019; 6:774-83.
104. Silberberg A, Tan MK, Yan AT, et al.; FREEDOM AF and CONNECT AF Investigators. Use of evidence-based therapy for cardiovascular risk factors in Canadian outpatients with atrial fibrillation: from the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF). *Am J Cardiol* 2017;120:582-7.
105. Bowker SL, Savu A, Yeung RO, et al. Patterns of glucose-lowering therapies and neonatal outcomes in the treatment of gestational diabetes in Canada, 2009-2014. *Diabet Med* 2017;34:1296-302.
106. Alkhiari R, Alzayer H, Aljazeera J, et al. Adherence to guidelines for inpatient pharmacologic management of type 2 diabetes in adults and glycemic outcomes. *Can J Diabetes* 2018;42:158-62.
107. Banihashemi B, Goodman SG, Yan RT, et al.; Global Registry of Acute Coronary Events. (GRACE/GRACE(2)) Investigators. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian Global Registry of Acute Coronary Events (GRACE) experience. *Am Heart J* 2009;158:917-24.
108. Kahn SR, Springmann V, Schulman S, et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. *Thromb Haemost* 2012;108:493-8.
109. Sauro K, Bagshaw SM, Niven D, et al. Barriers and facilitators to adopting high value practices and de-adopting low value practices in Canadian intensive care units: a multimethod study. *BMJ Open* 2019;9:e024159.
110. Panju M, Raso D, Patel A, et al. Evaluation of the use of venous thromboembolism prophylaxis in hospitalised medical patients. *J R Coll Physicians Edinb* 2011;41: 304-8.
111. Pai M, Lloyd NS, Cheng J, et al. Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. *Implement Sci* 2013;8:1.
112. Black E, Neville H, Losier M, et al. Antimicrobial use at acute care hospitals in Nova Scotia: a point prevalence survey. *Can J Hosp Pharm* 2018;71:234-42.
113. Singer A, Fanella S, Kosowan L, et al. Informing antimicrobial stewardship: factors associated with inappropriate antimicrobial prescribing in primary care. *Fam Pract* 2018;35:455-60.
114. Ahmed S, Tamblin R, Winslade N. Using decision support for population tracking of adherence to recommended asthma guidelines. *BMJ Open* 2014;4:e003759.
115. Bischof DA, Dodson R, Jimenez MC, et al. Adherence to guidelines for adjuvant imatinib therapy for GIST: a multi-institutional analysis. *J Gastrointest Surg* 2015;19:1022-8.
116. Elegbede AA, Gibson AJ, Fu H, et al. Real-world adherence to guideline-recommended treatment for small cell lung cancer. *Am J Clin Oncol* 2020;43:236-42.
117. Shurrab M, Crystal E, O'Donnell D, et al. The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population. *J Interv Card Electrophysiol* 2017;48:261-6.
118. Abdul-Razzak A, Lemieux L, Snyman M, et al. Description of continuous palliative sedation practices in a large health region and comparison with clinical practice guidelines. *J Palliat Med* 2019;22:1052-64.
119. McKinnon K, Jupp J, Ghosh S, et al. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. *Pediatr Blood Cancer* 2019;66:e27488.
120. De Silva DA, Synnes AR, von Dadelszen P, et al. Magnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP): implementation of a national guideline in Canada. *Implement Sci* 2018;13:8.
121. Cheng S, Arciero V, Goldberg H, et al. Population-based analysis of the use of radium-223 for bone-metastatic castration-resistant prostate cancer in Ontario, and of factors associated with treatment completion and outcome. *Cancer Manag Res* 2019;11:9307-19.
122. Barkun AN, Bhat M, Armstrong D, et al. Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. *CMAJ* 2013;185:E156-66.
123. Deis N, Findlay JM. Appropriateness of lumbar spine referrals to a neurosurgical service. *Can J Neuro Sci* 2010;37:843-8.
124. Bhatia RS, Bouck Z, Ivers NM, et al. Electrocardiograms in low-risk patients undergoing an annual health examination. *JAMA Intern Med* 2017;177:1326-33.
125. Kirkham KR, Wijeyesundera DN, Pendrith C, et al. Preoperative testing before low-risk surgical procedures. *CMAJ* 2015;187:E349-58.
126. Bonafide CP, Xiao R, Brady PW, et al.; Pediatric Research in Inpatient Settings (PRIS) Network. Prevalence of continuous pulse oximetry monitoring in hospitalized children with bronchiolitis not requiring supplemental oxygen. *JAMA* 2020;323:1467-77.

127. Gasmi S, Ogden NH, Leighton PA, et al. Practices of Lyme disease diagnosis and treatment by general practitioners in Quebec, 2008–2015. *BMC Fam Pract* 2017;18:65.
128. Sun LY, Gershon AS, Ko DT, et al. Trends in pulmonary function testing before noncardiothoracic surgery. *JAMA Intern Med* 2015;175:1410-2.
129. *Unnecessary care in Canada: technical report*. Ottawa: Canadian Institute for Health Information; 2017:1-50.
130. Snodgrass R, Naugler C. Use of the Papanicolaou test in women under 25 years of age in Southern Alberta. *J Obstet Gynaecol Can* 2014;36:320-3.
131. Symonds CJ, Chen W, Rose MS, et al. Screening with Papanicolaou tests in Alberta: Are we choosing wisely? *Can Fam Physician* 2018;64:47-53.
132. Pendrith C, Bhatia M, Ivers NM, et al. Frequency of and variation in low-value care in primary care: a retrospective cohort study. *CMAJ Open* 2017;5:E45-51.
133. McAlister FA, Lin M, Bakal J, et al. Frequency of low-value care in Alberta, Canada: a retrospective cohort study. *BMJ Qual Saf* 2018;27:340-6.
134. Bouck Z, Pendrith C, Chen X-K, et al. Measuring the frequency and variation of unnecessary care across Canada. *BMC Health Serv Res* 2019;19:446.
135. Bellai-Dussault K, Meng L, Huang T, et al. A 2-year review of publicly funded cell-free DNA screening in Ontario: utilization and adherence to funding criteria. *Prenat Diagn* 2020;40:164-72.
136. Morgen EK, Naugler C. Inappropriate repeats of six common tests in a Canadian city: a population cohort study within a laboratory informatics framework. *Am J Clin Pathol* 2015;144:704-12.
137. Birk-Urovitz E, Del Giudice ME, Meaney C, et al. Use of thyroid-stimulating hormone tests for identifying primary hypothyroidism in family medicine patients. *Can Fam Physician* 2017;63:e389-94.
138. Gill J, Barakauskas VE, Thomas D, et al. Evaluation of thyroid test utilization through analysis of population-level data. *Clin Chem Lab Med* 2017;55:1898-906.
139. Wintemute K, Greiver M, McIsaac W, et al. Choosing Wisely Canada campaign associated with less overuse of thyroid testing. *Can Fam Physician* 2019;65:e487-96.
140. Henderson J, Bouck Z, Holleman R, et al. Comparison of payment changes and Choosing Wisely recommendations for use of low-value laboratory tests in the United States and Canada. *JAMA Intern Med* 2020;180:524-31.
141. Ma I, Guo M, Viczko J, et al. Evaluation of a provincial intervention to reduce redundant hemoglobin A1c testing. *Clin Biochem* 2017;50:1253-5.
142. Lake S, Yao Z, Gakhal N, et al. Frequency of repeat antinuclear antibody testing in Ontario: a population-based descriptive study. *CMAJ Open* 2020;8:E184-90.
143. Kandalam V, Lau CK, Guo M, et al. Inappropriate repeat testing of complete blood count (CBC) and electrolyte panels in inpatients from Alberta, Canada. *Clin Biochem* 2020;77:32-5.
144. MacMillan TE, Gudgeon P, Yip PM, et al. Reduction in unnecessary red blood cell folate testing by restricting computerized physician order entry in the electronic health record. *Am J Med* 2018;131:939-44.
145. Welk B, Winick-Ng J, McClure JA, et al. The impact of the Choosing Wisely campaign in urology. *Urology* 2018;116:81-6.
146. Kirkham KR, Wijeyesundera DN, Pendrith C, et al. Preoperative laboratory investigations: rates and variability prior to low-risk surgical procedures. *Anesthesiology* 2016;124:804-14.
147. Cohen E, Rodean J, Diong C, et al. Low-value diagnostic imaging use in the pediatric emergency department in the United States and Canada. *JAMA Pediatr* 2019;173:e191439.
148. Schuh S, Babl FE, Dalziel SR, et al.; Pediatric Emergency Research Networks (PERN). Practice variation in acute bronchiolitis: a pediatric emergency research networks study. *Pediatrics* 2017;140:e20170842.
149. Bouck Z, Mecredy G, Ivers NM, et al. Routine use of chest x-ray for low-risk patients undergoing a periodic health examination: a retrospective cohort study. *CMAJ Open* 2018;6:E322-9.
150. Bhatia RS, Ivers NM, Yin XC, et al. Improving the appropriate use of transthoracic echocardiography: the Echo WISELY trial. *J Am Coll Cardiol* 2017;70:1135-44.
151. Tharmaratnam T, Bouck Z, Sivaswamy A, et al. Association between physicians' appropriate use of echocardiography and subsequent healthcare use and outcomes in patients with heart failure. *J Am Heart Assoc* 2020;9:e013360.
152. Remfry A, Abrams H, Dudzinski DM, et al. Assessment of inpatient multimodal cardiac imaging appropriateness at large academic medical centers. *Cardiovasc Ultrasound* 2015;13:44.
153. Landry BA, Barnes D, Keough V, et al. Do family physicians request ultrasound scans appropriately? *Can Fam Physician* 2011;57:e299-304.
154. Emery DJ, Shojania KG, Forster AJ, et al. Overuse of magnetic resonance imaging. *JAMA Intern Med* 2013;173:823-5.
155. Eddy K, Ednie A, Connell C, et al. Appropriate use of CT and MRI in British Columbia. *BCM J* 2013;55:22-5.
156. Simos D, Catley C, van Walraven C, et al. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. *CMAJ* 2015;187:E387-97.
157. Ferguson C, Low G, Fung C. Retrospective analysis of the computed tomography pulmonary angiogram utilization patterns in the emergency department. *Can Assoc Radiol J* 2019;70:388-93.
158. Wanis K, Oucharek J, Groot G. Quality of thyroid referrals in Saskatchewan. *Qual Prim Care* 2013;21:247-52.
159. Khoury M, Tolentino M, Haj-Ahmad Z, et al. Assessing appropriateness of CT and MRI referrals for headache and lumbar: a Canadian perspective on patient-centered referrals. *J Med Imaging Radiat Sci* 2019;50:506-13.
160. Skiffington J, Metcalfe A, Tang S, et al. Potential impact of guidelines for the prevention of cesarean deliveries in a contemporary Canadian population. *J Obstet Gynaecol Can* 2020;42:766-73.
161. Riddell CA, Kaufman JS, Strumpf EC, et al. Cervical dilation at time of cesarean delivery in nulliparous women: a population-based cohort study. *BJOG* 2017;124:1753-61.
162. Arbel Y, Qiu F, Bennell MC, et al. Association between publication of appropriate use criteria and the temporal trends in diagnostic angiography in stable coronary artery disease: a population-based study. *Am Heart J* 2016;175:153-9.
163. Mohareb MM, Qiu F, Cantor WJ, et al. Validation of the appropriate use criteria for coronary angiography. *Ann Intern Med* 2015;162:549-56.
164. Assmus MA, Beyer DB, Hanks J, et al. Quality and cost assessment of Canadian Urological Association microscopic hematuria guidelines in clinical practice: turning urine into gold. *Can Urol Assoc J* 2019;13:406-11.
165. Verma AA, Kumachev A, Shah S, et al. Appropriateness of peripherally inserted central catheter use among general medical inpatients: an observational study using routinely collected data. *BMJ Qual Saf* 2020;29:905-11.
166. Ho EC, Cheskes S, Angaran P, et al. Implantable cardioverter defibrillator implantation rates after out of hospital cardiac arrest: Are the rates guideline-concordant? *Can J Cardiol* 2017;33:1266-73.
167. Bernier R, Al-Shehri M, Raj SR, et al. A population-based study of adherence to guideline recommendations and appropriate-use criteria for implantable cardioverter defibrillators. *Can J Cardiol* 2018;34:1677-81.
168. Lee D, Hardy J, Wang X, et al. Site-specific rates of shock, therapy and death after ICD implantation in Ontario: report from the Ontario ICD Database. Toronto: ICES; 2011. Available: <https://www.ices.on.ca/Publications/Atlases-and-Reports/2011/Site-Specific-Rates> (accessed 2021 Apr. 29).
169. Scales DC, Golan E, Pinto R, et al. Improving appropriate neurologic prognostication after cardiac arrest. A stepped wedge cluster randomized controlled trial. *Am J Respir Crit Care Med* 2016;194:1083-91.
170. Spradbrow J, Cohen R, Lin Y, et al. Evaluating appropriate red blood cell transfusions: a quality audit at 10 Ontario hospitals to determine the optimal measure for assessing appropriateness. *Transfusion* 2016;56:2466-76.
171. Soril LJJ, Noseworthy TW, Stelfox HT, et al. A retrospective observational analysis of red blood cell transfusion practices in stable, non-bleeding adult patients admitted to nine medical-surgical intensive care units. *J Intensive Care* 2019;7:19.
172. Shih AW, Jamula E, Diep C, et al. Audit of provincial IVIG Request Forms and efficacy documentation in four Ontario tertiary care centres. *Transfus Med* 2017;27:122-31.
173. Tinmouth A, Thompson T, Arnold DM, et al. Utilization of frozen plasma in Ontario: a provincewide audit reveals a high rate of inappropriate transfusions. *Transfusion* 2013;53:2222-9.
174. Walker K, Shearkhani S, Bai YQ, et al. The impact of the Long-term Care Homes Act and public reporting on physical restraint and potentially inappropriate antipsychotic use in Ontario's long-term care homes. *J Gerontol A Biol Sci Med Sci* 2020;75:813-9.
175. Chin T, Kushner B, Dersch-Mills D, et al. Antibiotic utilization patterns in patients with ventilator-associated pneumonia: a Canadian context. *Can J Infect Dis Med Microbiol* 2016;2016:3702625.
176. Srigley JA, Brooks A, Sung M, et al. Inappropriate use of antibiotics and *Clostridium difficile* infection. *Am J Infect Control* 2013;41:1116-8.
177. Irfan N, Brooks A, Mithoowani S, et al. A controlled quasi-experimental study of an educational intervention to reduce the unnecessary use of antimicrobials for asymptomatic bacteriuria. *PLoS One* 2015;10:e0132071.
178. Daley P, Garcia D, Inayatullah R, et al. Modified reporting of positive urine cultures to reduce inappropriate treatment of asymptomatic bacteriuria among nonpregnant, noncatheterized inpatients: a randomized controlled trial. *Infect Control Hosp Epidemiol* 2018;39:814-9.
179. Silverman M, Povitz M, Sontrop JM, et al. Antibiotic prescribing for nonbacterial acute upper respiratory infections in elderly persons. *Ann Intern Med* 2017;166:765-74.
180. Trenaman SC, Hill-Taylor BJ, Matheson KJ, et al. Antipsychotic drug dispensations in older adults, including continuation after a fall-related hospitalization: identifying adherence to screening tool of older persons' potentially inappropriate prescriptions criteria using the Nova Scotia seniors' pharmacare program and Canadian Institute for Health's Discharge databases. *Curr Ther Res Clin Exp* 2018;89:27-36.

181. Kirkham J, Maxwell C, Velkers C, et al. Optimizing prescribing of antipsychotics in long-term care (OPAL): a stepped-wedge trial. *J Am Med Dir Assoc* 2020;21:381-7.e3.
182. Gagnon ME, Sirois C, Simard M, et al. Potentially inappropriate medications in older individuals with diabetes: a population-based study in Quebec, Canada. *Prim Care Diabetes* 2020;14:529-37.
183. Roux B, Sirois C, Simard M, et al. Potentially inappropriate medications in older adults: a population-based cohort study. *Fam Pract* 2020;37:173-9.
184. Rigby HB, Rehan S, Hill-Taylor B, et al. Antipsychotic prescribing practices in those with parkinsonism: adherence to guidelines. *Can J Neurol Sci* 2017;44:603-6.
185. Pasricha SV, Tadrous M, Khuu W, et al. Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study. *Pain* 2018;159:1562-8.
186. Falk J, Friesen KJ, Magnusson C, et al. Opioid prescribing by dentists in Manitoba, Canada: a longitudinal analysis. *J Am Dent Assoc* 2019;150:122-9.
187. Weir DL, Lee TC, McDonald EG, et al. Both new and chronic potentially inappropriate medications continued at hospital discharge are associated with increased risk of adverse events. *J Am Geriatr Soc* 2020;68:1184-92.
188. Iaboni A, Campitelli MA, Bronskill SE, et al. Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. *CMAJ Open* 2019;7:E582-9.
189. Sharma V, Weir D, Samanani S, et al. Characterisation of concurrent use of prescription opioids and benzodiazepine/Z-drugs in Alberta, Canada: a population-based study. *BMJ Open* 2019;9:e030858.
190. Martin L, Gillis C, Atkins M, et al. Implementation of an enhanced recovery after surgery program can change nutrition care practice: a multicenter experience in elective colorectal surgery. *JPEN J Parenter Enteral Nutr* 2019;43:206-19.
191. Clemens KK, Liu K, Shariff S, et al. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013. *Diabetes Obes Metab* 2016;18:607-14.
192. Sadatsafavi M, Tavakoli H, Lynd L, et al. Has asthma medication use caught up with the evidence?: a 12-year population-based study of trends. *Chest* 2017;151:612-8.
193. Marin JG, Beresford L, Lo C, et al. Prescription patterns in dialysis patients: differences between hemodialysis and peritoneal dialysis patients and opportunities for deprescription. *Can J Kidney Health Dis* 2020;7:2054358120912652.
194. Andrew MK, Purcell CA, Marshall EG, et al. Polypharmacy and use of potentially inappropriate medications in long-term care facilities: Does coordinated primary care make a difference? *Int J Pharm Pract* 2018;26:318-24.
195. Thomas RE, Nguyen LT, Jackson D, et al. Potentially inappropriate prescribing and potential prescribing omissions in 82,935 older hospitalised adults: association with hospital readmission and mortality within six months. *Geriatrics (Basel)* 2020;5:37.
196. *Drug use among seniors in Canada, 2016*. Ottawa: Canadian Institute for Health Information; 2018:1-69.
197. *Drug use among seniors on public drug programs in Canada, 2012*. Ottawa: Canadian Institute for Health Information; 2014:1-71.
198. Morgan SG, Hunt J, Rioux J, et al. Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. *CMAJ Open* 2016;4:E346-51.
199. Papastergiou J, Luen M, Tencaliuc S, et al. Medication management issues identified during home medication reviews for ambulatory community pharmacy patients. *Can Pharm J (Ott)* 2019;152:334-42.
200. *Health care in Canada, 2011: a focus on seniors and aging*. Ottawa: Canadian Institute for Health Information; 2011:1-162.
201. McCracken R, McCormack J, McGregor MJ, et al. Associations between polypharmacy and treatment intensity for hypertension and diabetes: a cross-sectional study of nursing home patients in British Columbia, Canada. *BMJ Open* 2017;7:e017430.
202. Baselyous Y, De Cocinis M, Ibrahim M, et al. Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. *Expert Opin Drug Saf* 2019;18:153-61.
203. Maclagan LC, Maxwell CJ, Gandhi S, et al. Frailty and potentially inappropriate medication use at nursing home transition. *J Am Geriatr Soc* 2017;65:2205-12.
204. Mafi JN, Parchman M. Low-value care: an intractable global problem with no quick fix. *BMJ Qual Saf* 2018;27:333-6.

Competing interests: Alan Katz is a member of the ICES Scientific Advisory Committee and the SAIL International Advisory Board. He is president of the Canadian Association for Health Services and Policy Research and a member of the Board of Directors of The College of Family Physicians Canada. No other competing interests were declared.

This article has been peer reviewed.

Affiliations: Ottawa Hospital Research Institute (Squires, Cho-Young, Aloisio, Graham, Santos, Grimshaw); School of Epidemiology and Public Health (Graham), School of Nursing (Squires, Demery Varin, Greenough, Nadalin-Penno, Vandyk) and Department of Medicine (Grimshaw), University of Ottawa, University of Ottawa, Ottawa, Ont.; Department of Surgery (Bell), Dalla Lana School of Public Health (Dobrow), Department of Medicine (Levinson), and Department of Family and Community Medicine (Tepper), University of Toronto, Toronto, Ont.; Division of Community Health and Humanities (Bornstein), Memorial University of Newfoundland, St. John's, Nfld.; Public Reports (Brien), Health Quality Ontario, Toronto, Ont.; Faculty of Medicine (Decary), University of Montreal, Montréal, Que.; Faculty of Nursing (Estabrooks), University of Alberta, Edmonton, Alta.; Registered Nurses Association of Ontario (Grinspun); Ontario Ministry of Health and Long-Term Care (Hillmer), Toronto, Ont.; Royal College of Physicians and Surgeons of Canada (Horsley), Ottawa, Ont.; Virginia Commonwealth University (Hu), Richmond, Va.; Family Medicine (Katz), University of Manitoba, Winnipeg, Man.; BC Patient Safety and Quality Council (Krause), Vancouver, BC; Clinical Epidemiology and Biostatistics (Lavis) and McMaster Health Forum (Wilson), McMaster University, Hamilton, Ont.; Department of Community Health and Epidemiology (Levy), Dalhousie University, Halifax, NS; New Brunswick Health Council (Mancuso), Moncton, NB; Faculty of Medicine (Morgan), The University of British Columbia, Vancouver, BC; Health Quality Council of Alberta (Neuner), Calgary, Alta.; Canadian Agency for Drugs and Technologies in Health (Rader), Ottawa, Ont.; Alberta Health Services (Teare), Edmonton, Alta.

Contributors: Janet Squires and Jeremy Grimshaw conceived the study. Tamara Rader developed and ran the search strategy. Janet Squires, Danielle Cho-Young, Laura Aloisio, Simon Decary, Melissa

Demery Varin, Megan Greenough, Letitia Nadalin-Penno and Wilmer Santos contributed to screening, data extraction or quality assessment. Janet Squires, Danielle Cho-Young, Laura Aloisio and Jeremy Grimshaw completed the synthesis with input and critical revision from all authors. Janet Squires drafted the manuscript. All of the authors contributed to development of the study design, reviewed and revised the manuscript critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e., research or educational use), and no modifications or adaptations are made. See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Funding: This research was supported by a Canadian Institutes of Health Research (CIHR) Project Grant. The CIHR had no role in the study's design, conduct and reporting. Janet Squires holds a University of Ottawa Research Chair in Health Evidence Implementation. Carole Estabrooks holds a Canada Research Chair in Knowledge Translation (care of older adults). John Lavis holds a Canada Research Chair in Evidence-Informed Health Systems. Jeremy Grimshaw holds a Canada Research Chair in Health Knowledge Transfer and Uptake. Michael Hillmer has received research grants from CIHR and the Public Health Agency of Canada. Alan Katz has received research grants from CIHR.

Data sharing: The search strategy, extracted data, and quality assessment are in the appendices. Citations for all included studies are in manuscript references. Other data sets from this study are available upon reasonable request from the corresponding author.

Acknowledgement: The authors would like to thank Caitlyn Ford (Manager, Research Information Services, Canadian Agency For Drugs And Technologies In Health) for PRESS reviewing our search strategy.

Accepted: Dec. 16, 2021

Correspondence to: Janet Squires, janet.squires@uottawa.ca